To more significantly improve the effector functions in all patients a combination of blocking several checkpoint inhibitors may be required, as indicated by PD-1/CTLA-4 blocking in cancer studies (76, 77) Furthermore, the increase of effector function is similar when EBV-specific CD8+ T cells from APDS patients are compared with HIV-specific T cells from HIV-infected patients and within the range reported previously for HIV-specific CD8+ T cells (41, 44, 45). This evidence concerns the gene CD8A and cancer.